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Cancers are usually advanced when diagnosed . An important problem in
developing immunotherapy to cancer is to determine whether such advanced
cancers express antigens that can serve as specific targets for immune destruction .
Murine skin tumors induced by UV are especially suited for study of changes in
the expression of tumor-specific antigens during development of cancer (re-
viewed in reference 1) . The "parental" UV-induced tumors are usually highly
immunogenic and regress (RE)' when transplanted into normal immunocompe-
tent mice, but will usually grow progressively in T cell-deficient or nude mice .
Rarely, however, do these tumors give rise to variants that grow progressively in
normal mice (2) . The progressor (PRO) variants lose antigens recognized by
CTL (2), so that "tumor progression" (3, 4) leading to an advanced cancer
apparently results from Darwinian selection by immunologic and possibly other
homeostatic defense mechanisms (5, 6) .
We have previously shown (2) that PRO variants derived from the UV-induced
tumor 1591-RE have lost a tumor-specific antigen recognized by CTL, and this
antigen was designated the "A" antigen . We suspected that PRO tumor variants
retained additional antigens, since a relatively larger tumor inoculum (>107) of
these variant tumor cells was required for growth in normal mice as compared
with the number oftumor cells (:5106) needed for outgrowth in T cell-deficient
nude mice, and because the tumor take in normal mice was only ^"80% of that
in nude mice (2) . Indeed, we found that 1591-PRO variants could be rejected
and did induce specific CTL if mice were first immunized with RE or a
subtumorigenic number of PRO tumor cells (7) ; we therefore considered the
1591-PRO variants to still express other antigens, designated "B" (8) .
In this paper, we now describe a highly malignant (HM) variant of 1591 that
metastasizes, grows even in immune hosts, and that has lost all known CTL-
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defined antigens. This HM variant, however, as well as all other tumors of the
1591 lineage, retain antigen(s) recognized by Th cells. Such Th-recognized
tumor-specific antigens may, therefore, represent potential targets for immuno-
therapy.
Materials and Methods
Mice.
￿
4-10-wk-old germ-free-derived, specific pathogen-free female C3H/HeN mam-
mary tumor virus (MTV)-negative mice were purchased from the National Cancer
Institute Frederick Cancer Research Facility, Bethesda, MD. The mice were housed at
the La Rabida Institute in laminar flow hoods. Original stock of nude C3H/HeN mice
used to breed a nude C3H colony were in the twenty-third backcross generation when
they were obtained from a colony at the Biology Division of the Oak Ridge National
Laboratory, Oak Ridge, TN. To prepare immunodeficient mice, 4-wk-old C3H mice were
thymectomized, irradiated (900 rad,
137Cs source), and then bone marrow reconstituted
a wk later (9).
Monoclonal Antibodies.
￿
The hybridomas secreting anti-Thy-1 .2 (AT83A), anti-Lyt-2
(3.155), and anti-L3T4 (GK 1 .5) were a kind gift of Dr. Frank W . Fitch of the University
of Chicago. The anti-H-213k (15 .5.5) hybridoma was a gift of Dr. David Sachs, National
Cancer Institute, Bethesda, MD. Anti-I-Ak (10-2.16) and anti-H-2Kk (11-4 .1) h~bridomas
were obtained from the Salk Cell Distribution Center (LaJolla, CA) and anti-I-E (17.3.3S)
was from the American Type Culture Collection, Rockville, MD.
Tumor Lines and Variants.
￿
The RE fibrosarcomas 1591-RE, 1316-RE, and 2240-RE
were induced in C3H/HeN(MTV-) mice by repeated exposure to UV light (10) and the
RE fibrosarcoma 1130-RE was induced in a UV-irradiated C3H/HeN(MTV-) mouse by
subcutaneous injection of 3-methylcholanthrene under the unshaved ventral skin. The
immunogenic RE tumors grow initially for 1-2 wk in young syngeneic mice but then
regress. Regression occurs even when large doses of the tumor are injected, e.g., multiple
1-mm3 tumor fragments, while much smaller tumor grafts grow progressively and kill
immunodeficient or nude mice (11). Noncrossreacting, tumor-specific antigens have
previously been shown on these tumors using transplantation assays (11), and through the
generation of CTL (2, 10, 12) and mAb probes (13).
PRO tumors 1591-PROA (2) and 1316-PROA (referred to in this paper as 1591-PRO
and 1316-PRO) were reisolates from rare tumors (<5%) that grew progressively in normal
mice challenged with the parental 1591-RE and 1316-RE. These variants grow progres-
sively upon subsequent transplantation in -80% of young immunocompetent mice (2),
and they kill the host through local invasion, without macroscopic evidence of distant
metastases. As a result of immunoselection by the normal host, the 1591-PRO variants
have lost a 1591-tumor-specific antigen (designated A) that is only expressed on 1591-RE
tumors (7, 8). The 1591-PRO tumors retain another 1591-specific tumor antigen desig-
nated B, which is recognized by CTL from 1591-PRO-immunized mice (7, 8). 1591-AS6
(A-B+) and 1591-BSI (A+B-) (referred to here as 1591-AS and 1591-BS, respectively)
were selected in vitro by CTL specific for the A and B determinants, respectively (8). The
induction of MHC class II antigens has been reported for some tumors after manipulation
of tumor cells in vitro and in vivo (14), but such antigens were not inducible in the 1591
tumors by culture with recombinant IFN--y (Genentech, Inc., San Francisco, CA) or
secondary mixed lymphocyte culture supernatants (8), although these factors induced an
increased expression of class I antigens. Furthermore 1591-RE did not express detectable
levels of class II antigen when tissue sections of tumors isolated during rejection were
stained by immunoperoxidase using I-A+ tumor-associated macrophages as positive con-
trols (C. Van Waes, unpublished results).
All tumors have been adapted to tissue culture, expanded for 2 wk, and cryopreserved
in aliquots. Aliquots were thawed and used within 1-3 d for all experiments. All cell lines
used were routinely examined for and found to be free of mycoplasma by Hoechst 33258
(Flow Laboratories, Inc, McLean, VA) DNA staining. Tissue culture lines were injected
into C3H nude or immunodeficient mice to obtain solid tumor fragments for immuniza-VAN WAES ET AL.
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tion or challenge in most experiments. The solid tumors were finely minced in cold MEM
and three 1-mm' fragments were injected subcutaneously in the inguinal region of mice
by a trocar. This precaution was taken to prevent priming Th cells to heterologous serum
components of tissue culture medium.
Delayed-Type Hypersensitivity (DTH) Assay.
￿
A DTH response is defined as an antigen-
specific, T cell-dependent, cutaneous inflammatory reaction with a peak intensity at 24-
48 h after antigen challenge of a preimmunized animal (15). DTH reactions can be
sensitively measured by an ear swelling assay (16, 17) that we have adapted for testing
DTH responses to live tumor cells. In the DTH assay, responses of unsensitized mice or
mice sensitized with three 1-mm' tumor fragments 8 d previously were elicited with 2 X
105 tumor cells suspended in 10 Al culture medium. The injection for elicitation was given
subcutaneously on the outer dorsal surface ofboth ears using a precision syringe (71 OLT;
Hamilton Co., Reno, NV) and a 30 g needle. The increment in ear thickness represents
the average difference between three prechallenge and three 24-h postchallenge meas-
urements using a precision spring-loaded dial caliper (Mitutoyo No. 7326; Precision Gage
Co., Chicago, IL). The measurements were carried out independently by two investigators
who did not know the identity of the experimental groups. Controls in all experiments
included comparison of immune and nonimmune mice, and immune mice challenged
with the related and unrelated tumor cells in opposite ears, to show that the DTH
responses required priming and were antigen specific. Pilot experiments (not shown)
confirmed that the ear swelling had the characteristic peak at 24-48 h followed by decay
of swelling, which excluded the possibility that swelling was simply due to growth of
tumor. For adoptive transfer assay of DTH, the hind footpads of nonimmune recipients
were each injected with 3 X 106 nonimmune or immune spleen cells and 2 X 105 tumor
cells suspended in 50 jl of hybridoma culture supernatant from the monoclonal anti-
L3T4 hybridoma or from the nonsecreting fusion partner cell line. Pre-and postchallenge
measurements were carried out with the leg fully extended using a precision spring-loaded
dial caliper (Mitutoyo No. 7300; Precision Gage Co.).
Assayfor Th In Vitro.
￿
Tumor-specific Th cells were detected in vitro by coculture with
cloned IL-2-dependent CTL that were tested for cytotoxicity against tumor targets at the
end of a 7-d culture period (18). The number of spleen cells containing optimal numbers
of Th as predetermined by limiting dilution analysis were added to microcultures contain-
ing 2 X 10' mitomycin C-treated tumor cells as antigen, 3 X 105 irradiated (2,000 rad)
T cell-depleted filler spleen cells, with cloned CTL (10' anti-1591-A or 200 anti-2240)
for detection of IL-2. Cultures were set up in 6 X 50 mm round-bottomed glass tubes
(Kimble Div., Owens-Illinois, Inc., Toledo, OH) containing a volume of 0.4 ml mixed
lymphocyte-tumor culture (MLTC) medium. After 7 d of incubation, we resuspended
cultures by pipetting, and we split two 150-,1 aliquots to corresponding wells of two
microtitration plates to which we added the specific or an unrelated "Cr-labeled tumor
target in 50 j1 medium. In some experiments, the phenotype of responder cells was
assayed by depletion of Thy-1 .2+ or Lyt-2+ cells before culture using the AT83A or 3.155
mAb and rabbit complement, as described (2). In other experiments, the ability of anti-1-
A', anti-L3T4, or anti-thy-1 .2 antibody to functionally block precursor Th activity by
addition to microcultures in the absence of complement was assayed with or without the
addition of supernatant containing added IL-2. For the Poisson analysis of the limiting
dilution assay, cultures containing responder cells were scored "negative" for Th activity
when the specific release of "Cr by the CTL in these cultures <3 SD above the mean
"Cr release caused by CTL without responders (control cultures; 18). Th precursor
frequencies were calculated using the maximum likelihood method of Finney (19) as
modified by Porter and Berry (20), and the minimum X 2 method presented by Taswell
(21). The "relative cytolytic activity" for cultures of different responder cell numbers was
also analyzed as described by Coppleson and Michie (22).
Cytolytic T Cells and Lines. To generate CTL, spleen cells from tumor-immunized
animals were restimulated in vitro in a 7-d MLTC (2). Continuous anti-1591 (anti-A) and
anti-2240 CTL, lines were derived by cloning the CTL generated in MLTC with mito-
mycin C-treated tumor cells as stimulator cells, irradiated (2,000 rad) spleen cells as fillers1550
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cells, and a supernatant from secondary mixed lymphocyte cultures as a source of IL-2
(8) . The resultant lines were L3T4-, Lyt-2+, tumor-specific, and IL-2-dependent (8) for
growth.
Chromium Release Assay. Target cells (1-2 X 106) were labeled with 100 ACi "Cr
(Amersham Corp., Arlington Heights, IL) for 1-2 h at 37 °C in a volume of 200 Al. Cells
were washed twice with 1 ml of medium before addition of 2-5 X 10s targets per well
containing effector cells from helper assay cocultures or MLTC. CTL effector cells
generated in MLTC were serially diluted in V-bottomed 96-well microtiter plates just
before the addition of labeled target cells. 0.1 ml of supernatant from the 0.2 ml cultures
was removed after 4-6 h ofincubation at 37 °C, and the released radioactivity was counted
in a gamma counter. The percentage of lysis was calculated by the formula: [(experimental
release-spontaneous release)/(total release-spontaneous release)] X 100 .
Cytofluorometric Analysis.
￿
Methods for quantifying levels ofnormal MHC classI surface
antigen expression on the surface of tumor cells have been described (23). Briefly, 106
cells were incubated with a saturating concentration of the first antibody for 20 min at
4'C . The cells were then washed twice and resuspended in PBS containing 0.1 sodium
azide and fluorescein-coupled goat anti-mouse Ig (Hyclone 5 1081-A; HyClone Labora-
tories, Logan, UT). After 20 min, cells were washed twice again and 104 cells were
analyzed on a FACS IV (Becton Dickinson Immunocytometry Systems, Mountain View,
CA.). The number of cells was plotted as a function of the fluorescence intensity in
arbitrary units obtained using a log amplifier.
Results
Loss of CTL-defined, Tumor-specific Antigens during Tumor Progression.
￿
We
previously found (7, 24) that selection for locally invasive 1591-PRO variants of
the 1591-RE tumor required loss of the A antigen recognized by 1591-RE-
specific CTL. The 1591-PRO variant, in turn, retained a less immunogenic B
antigen defined by CTL (7, 24). In the present study, we sought to derive more
malignant variants of the UV-induced tumor 1591 by further selection of 1591-
PRO in vivo, and determine if further antigen loss was associated with these
changes in malignancy. Thus, two 1-mm2 tumor fragments of 1591-PRO and
10' spleen cells from 1591-PRO-immune mice were coinjected into nude C3H
mice in a Winn-type assay (25). The growth of tumors in mice coinjected with
1591-PRO immune cells was inhibited when compared with that of tumors
coinjected with normal cells or medium only as controls (Fig. 1). Tumors grew
rapidly in all animals that received normal (nonimmune) or no spleen cells, and
these mice died 22-30 d after challenge. In contrast, all mice that received the
mixture of immune spleen cells and tumor cells were initially protected during
this period, and only later did progressive tumor growth overcome these mice.
Such a progressively growing tumor was reisolated from one of these mice at
day 50, and it was transplanted into normal mice. The transplanted reisolate was
found to grow and invade rapidly and to develop distant metastases. Based on
these characteristics, the variant was designated 1591-HM, because it was a
highly malignant variant of the 1591 tumor. The increase in malignancy after
selection was seen by comparison of the survival of normal mice challenged with
the 1591-HM variant with that of mice challenged with the 1591-PRO variant
(Fig. 2). The 1591-HM variant was more malignant than the 1591-PRO variant
from which it was derived, since it killed all mice within 35 d, whereas the
original 1591-PRO tumor required 120 d before it killed 50% of the mice by
local growth . In addition to the 1591-HM variant, we reisolated an additionalE
d
7
O
O
E
FIGURE 1 .
￿
Temporary inhibition of the outgrowth of 1591-PRO tumor cellsby 1591-PRO
immune cells leading to immune selection for 1591-HM tumor variants. 1591-PRO tumor
cells either aloneor mixed with either normal or immune spleen cells were injected subcuta-
neously into nude mice in a Winn-type assay (25). Immune spleen cells were from animals
injected twice with a sublethal dose of 10' 1591-PRO tumorcells 4 wk apart. 108 spleen cells
from either normal or immunized mice were injected with two 1-mm' fragmentsof the 1591-
PROtumor. Tumor volumes were determined by caliper measurements in threedimensions.
Vertical bars represent theSEM for three animals tested in two separate experiments.Animals
not receiving immune spleen cells died between 22 and 30 d after challenge. The animals
receivingimmune cells were all alive 50 dafter implantation; at this time themice were killed
for readaptation of the progressively growing tumors to tissue culture. These lines were
designated 1591-HM.
VAN WAES ET AL.
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FIGURE 2.
￿
Highly malignant behavior of 1591-HM reisolated after immune selection from
1591-PRO tumor cells. Five normal C3H mice per group were each injected subcutaneously
with two 1-mm' fragments of variants 1591-PRO or 1591-HM or the parental tumor 1591-
RE. The rapid death of mice injected with 1591-HM reflected more rapid growth of this
tumor when compared with the 1591-PRO variant from which it was selected. For definition
of the CTL-defined antigenic phenotypes Aand B, consult Fig. 3.
tumor cell line from an axillary metastasis of 1591-HM, which also regularly
metastasized on transplantation, and have called this metastatic tumor cell line
1591-MET. Thus, both 1591-HM and 1591-MET represented HM variants of
the 1591 tumor.
We next asked if complete loss of the 1591-specific A and B antigens resulted
from the step-wise in vivo selection resulting in the 1591-HM variant. Anti-A
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FIGURE 3.
￿
Loss of A and B antigens recognized by CTL during variant selection. To raise
1591 tumor-specific CTL, mice were immunized twice with 1591-RE (anti-A), 1591-PRO
(anti-B),or 1591-HM tumorcells inactivated by 10,000 rad to prevent outgrowthof the 1591-
PRO and 1591-HM variants. Spleen cells from these mice were restimulated in vitro with
appropriate tumor cellsinactivated with mitomycin C (2). BALB/c anti-C3H allospecific CTL
were stimulated in a primary mixed lymphocyte culture to test the sensitivity of the tumor
variants to CTLspecific foranontumor antigen (H-2'alloantigen). Thecytotoxicity ofeffector
cells recovered after 7 d of culture was tested in a 5-h 5'Cr release assay against the various
"Cr-labeled target cells(see legend).
and anti-B CTL were generated from 1591-RE and 1591-PRO immune spleen
cells in MLTC and the susceptibility of the sequentially selected variants of the
1591 lineage to lysis was tested in a "Cr-release assay. As shown in Fig. 3, a and
b, the 1591-HM variant was lysed by neither 1591-RE (anti-A)- nor 1591-PRO
(anti-B)-specific CTL. The insensitivity of the 1591-HM tumor to 1591-specific
CTL could be due to (a) loss of the target antigens, (b) resistance to the lethal
hit delivered by CTL, or (c) loss of MHC class I, K, and D antigens which restrict
CTL responses (26). Antigen loss is the most likely basis of insensitivity to lysis
since 1591-HM was not only resistant to lysis by anti-A and anti-B CTL, but
also failed to induce anti-A or anti-B CTL that could lyse targets 1591-RE and
1591-PRO in the same experiment (Fig. 3, a-c). Further, we have excluded the
second alternative explanation by showing that 1591-HM tumor cells remained
susceptible to the lethal hit by CTL that reacted with C3H H-2k alloantigen (Fig.
3d). Finally, the failure of the 1591-HM variant to be lysed by anti-A or anti-B
CTL could not be accounted for by loss of MHC class I, K, and D antigens,
because the 1591-HM variant had not lost MHC class I antigens recognized by
class I alloreactive CTL (Fig. 3d), or class I-specific mAbs (Fig. 4). Therefore,
the phenotypes of the tumors have been designated 1591-RE [A'B'], 1591-PRO
[A-B+], and 1591-HM [A-B-J, according to sensitivity to 1591-specific CTL, as
in Fig. 3 . Together, the above experiments are consistent with the hypothesis
that multiple tumor-specific antigens that are recognized by CTL were lost with
tumor progression.
Retention of Th-defined, Tumor-specific Antigens by Malignant Variants.
￿
The
selection of an HM variant that has lost CTL-defined antigens should make it
possible to determine whether an independent antigen recognized by Th cells
exists and is retained despite tumor progression. We tested whether the 1591
variants expressed antigens recognized by tumor-specific Th cells in an ear
swelling assay that measures DTH responses (16, 17). Responses of unsensitizedO
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￿
Retention of MHC class I antigens by 1591-PRO and 1591-HM. Tumor cells
were incubated with class I-reactive mAb 11-4.1 (Kk) or 15 .5 .5 (Dk) (solid bars), class 11
reactive mAb 10.2 .16 (I-A') or 17 .3 .3 (I-Ek), or T lymphocyte-reactive mAb GK1.5 (L3T4)
and 3.155.3 (Lyt-2) (openbars) as the first antibody as indicated. Allsampleswere then washed
and incubated with fluorescein-coupled goat anti-mouse antibody as asecond step. Theamount
of fluorescence for 10' cells was quantified using a FACS IV. Binding ratio represents the
ratio of the mean fluorescence ofstaining with both first andsecond antibodies dividedby the
mean fluorescence of staining with thesecond antibody alone (background fluorescence). The
useof the binding ratio allows a comparison between different cell lines that may differ in the
amount ofbackground fluorescence. Mean binding ratios ar calculated from twoindependent
experiments that were similarand thereforepooled. 1591-PRO and 1591-HM tumor cellsdo
not express MHC class II antigens (A',E'), nor could class II antigens be induced in vitro by
treatmentwith IFN-y (not shown).
mice and mice sensitized by injection of 1591-RE or 1316-RE tumor fragments
were elicited after 8 d with the parental 1591-RE and 1316-RE tumors and their
variants. Fig. 5 shows that the 24-h ear swelling responses elicited by 1591 or
1316 cells are tumor-specific, in that they require specific sensitization and
elicitation with the same tumor. In the same experiments, we found that tumor
variants that had lost the 1591 CTL-defined tumor antigens also elicited the
1591-specific DTH responses (Fig . 5, left). To our surprise, the DTH responses
elicited by challenge with the variants 1591-HM and 1591-MET were not
reduced despite the loss of the CTL-defined A and B antigens. Although Fig. 5
only shows tumor-specific DTH immunity elicited by the 1591 tumor variants,
such A-B- 1591 variant cells could also sensitize for 1591-specific DTH re-
sponses. Thus, we saw that the DTH swelling responses (x 10-3 cm) elicited by
1591-RE tumor cells in 1591-RE- (5.5 ± 0.7), 1591-PRO- (6.4 ± 2.0), and 1591-
HM- (5 .9 ± 0.7) sensitized mice were similar and significantly greater (p < 0.01)
than responses elicited by the 1316 tumor (-1.0 ± 0.6, 0.2 ± 0.5, and 0.4 ± 0.4,
respectively). These results indicate that an antigen found on all tumors of 1591
lineage, but not on any other UV-induced tumor tested (i.e., 1316-RE, Fig. 5;
2240-RE or 1463-RE, ref. 27) can sensitize as well as elicit 1591 tumor-specific
DTH independent of expression of antigens recognized by tumor-specific CTL.
The finding of a retained tumor lineage-specific antigen on PRO variants has
been extended to another tumor, since Fig. 5 (right) shows that 1316-PRO
variant cells also retain a 1316 tumor lineage-specific DTH-inducing antigen.
To confirm that the DTH responses to 1591 were mediated by the L3T4+ Th
subset, we tested if the response could be blocked by L3T4-specific mAb in a
local adoptive transfer footpad swelling assay (see Materials and Methods). 1591-
RE-sensitized spleen cells, but not unsensitized spleen cells, were found to1554
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FIGURE 5 .
￿
Retention of a tumor-specific, DTH-inducing antigen during tumor progression .
The DTH responses are "tumor lineage-specific," i . e., all tumor cells and variants derived
from the same parental tumor (but not from another independently derived tumor) express
the same antigen . Mice were sensitized with three 1-mm s tumor fragments of 1591-RE or
1316-RE, or remained unsensitized . 1591-RE, 1316-RE, 1591-PRO, 1316-PRO, 1591-HM,
or 1591-MET tumor cells were used for elicitation 8 d later . The difference in ear swelling
responses between sensitized and unsensitized mice (± SE of the difference) are shown at 24
h after elicitation with the RE and the variant tumor cells . The bars represent measurements
from two to three independent experiments, each with five mice per group that were similar
and therefore pooled . Responses elicited by tumor cells in immune mice were greater than
those of nonimmune controls as long as sensitization and elicitation were carried out using
tumor cells of the same lineage (p < 0.05) . The responses to 1591-PRO and 1591-MET (but
not to 1316-RE) were significantly greater than in nonimmune control mice (p < 0.01),
indicating the retention of a 1591 tumor-specific, DTH-inducing antigen during tumor
progression of the 1591 tumor .
produce a local DTH response 24 h after coinjection with 1591 tumor cells (6.9
X 10-2 cm increase in thickness above the swelling of 1 .0 X 10-2 cm transferred
by unsensitized spleen cells; p< 0.05; five mice per group) . The addition of anti-
L3T4 antibody (but not of nonsecreting parent hybridoma supernatant used as
control) blockedthe response (0.2X 10-2 cm swelling above nonimmunecontrol) .
These results indicated that the DTH response to the 1591 tumor was mediated
by an L3T4' Th cell, which is distinct from the Lyt-2+ phenotype of 1591-
specific CTL (2) .
The findings above indicated the existence ofa 1591 lineage-specific antigen
that is retained on the HM tumor variants 1591-HM and 1591-MET . We next
investigated whether the Th response to this tumor lineage-specific antigen
could be defined in vitro . We first determined if Th cells were required for the
generation of 1591-specific cytolysis in vitro and ifTh could be detected reliably
andcharacterized underlimiting dilution conditions in a 7-dMLTC microculture
assay (for details see Materialsand Methods) . Dilutions of spleen cells from 1591-
immune mice were cultured with excess numbers of tumor cells as antigen and
APCs to increase the likelihood that titrated immune lymphocytes would be the
limiting population . The number of cultures that lysed 1591-RE in a 51Cr-release
assay was scored and the percentage of nonresponding cultures was plotted as a
function of number of titrated 1591 immune cells (Fig. 6a, filled circles) ; theVAN WAES ET AL .
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curved plot that resulted indicated that cytolysis was generated by a multihit
kineticsand, therefore, was dependent on more than one limitingcell per culture.
The slope of a plot of the mean cytolytic response as a function of number of
titrated immune cells using the analysis of Coppleson and Michie (Fig. 6b,
reference 22) provided an estimate of approximately two interacting cell types.
Thus, on the hypothesis that a Th cell would be the remaining limiting cell if
IL-2-dependent, tumor-specific CTL were present in excess, we added cloned
1591-specific CTL, which depend upon Th-derived growth factor (IL-2) for
proliferation (8). Asshown in Fig. 6a, addition oflimiting but increasing numbers
of immune cells to an excess of cloned CTL (open squares) produces a linear
increase in the numbers of positive cultures, verifying that a single cell type was
limiting under conditions of the assay. The limiting cell type was found to be a
T cell belonging to the Lyt-2- Th subset, since treatment of the immune spleen
cells with complement and anti-Thy-1, but not anti-Lyt-2, eliminated the help
for the response of the cocultured CTL line (Fig.6 c). To test whether these Th
cells were specific for 1591 antigen, 1591 immune cells were cocultured with
CTL against ao unrelated antigen, 2240-RE. Fig. 6d shows that in the absence
of 1591-RE tumor cells, 1591 immune cells failed to provide help, while upon
addition of 1591-RE antigen we saw an increase in response of 2240-specific
CTL. Together, the experiments in Fig. 6 show that the response of CTL in
vitro depends upon the presence of tumor-specific Th cells. Furthermore, the
experiments document the quantitative response of indicator CTL as a function
of dose of Th since, in the range of 109-2 x 105 immune cells per culture, the
cytolytic activity of the cloned CTL increased proportionally with the increase
in numbers ofimmune cells.
We next investigated whether 1591 tumor variants expressed a 1591 tumor
lineage-specific antigen that was recognized by Th in vitro. Thus, we cultured
different tumor cells as a source ofantigen, together with a single concentration
of Th, CTL, and APCs, as determined to be optimal in the limiting dilution
experiments above. We first tested if 1591 variants expressing different combi-
nations of the A and B antigens (8) shared an additional antigen that was not
defined by CTL. Exp. 1 ofTable I shows that sharing ofthe CTL-defined, 1591-
specific antigens between the sensitizing and eliciting tumor cells did not seem
to be required for generation of 1591-specific help. Thus, Th cells sensitized by
A-B+ tumor cells were restimulated by an A+B- tumor variant in coculture. This
indicates that the 1591 tumors express a lineage-specific, Th-recognized antigen
independently of the CTL-defined antigens . Exp. 1 also confirms that the
elicitation of help for the CTL in vitro was antigen-specific since it required
sensitization in vivo with tumors of the 1591 lineage (i.e., spleen cells of mice
immunized with another UV- or a methylcholanthrene-induced tumor did not
provide help). In addition, the 1591 lineage-specific Th cells were blocked by
anti-L3T4 and anti-I-Ak but not anti-Thy-1 antibodies in the absence ofC' (Exp.
2), suggesting that the 1591 antigen-specific cells providing help for CTL in
vitro had a classical Th cell phenotype. Similar results were obtained using
parental 1591-RE tumor cells as antigen in Exps. 3 and 4 of Table 1, which also
show that the blocking effect of anti-L3T4 could be abrogated by the addition
ofIL-2.TABLE I
Sensitization and Elicitation ofTh Requires Sharingofthe TumorLineage-specific Antigen
that Is Independent of the CTL-defined Tumor-specific Antigens
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* Nonimmune, 2240-RE, 1130-RE, 1591-RE [A+B+], 1591-BS [A+B-], 1591-AS [A-B+] tumor-
immune spleen cellswere cultured with a 1591-specific IL-2-dependent cytolytic T cell line (which
is used as a readout for 11-2 production by Th cells), mitomycin c-treated stimulating tumor cells
and T cell-depleted filler spleen cells in a limiting dilution assay (for details see Materials and
Methods). The 1591-specific, CTL-defined anti enic phenotypes are shown in brackets.
*Anti-Thy-1 .2, anti-L3T4, anti-I-Ak, or anti-D
￿
mAb or secondary mixed lymphocyte culture
supernatant as a source of IL-2 were added at a 1:10 dilution at initiation ofculture.
§ Numbersrepresentthe mean percent lysis ±SEM for 8 replicate cultures in Exps. 1 and 2, and 16
replicates in Exps. 3 and 4 in a 6-h 5'Cr-release assay after 7 d of culture. Lysis of the unrelated
target 2240-RE in duplicate assay was 0% in Exp. 1, <_3% in Exp. 2, :51% in Exp. 3, and :58% in
Exp. 4 for allculture groups.
A The failure to elicit help from spleen cells of mice injected with the tumors unrelated to 1591 in
Exp. 1 wasapparently not due to less efficient priming by these tumors. This is suggested by the
fact that 2240-RE immune spleen cells from the same group of mice provided help when the
relevant tumorantigen to which they had been immunized (2240-RE cells) was added (not shown).
" Mean response is significantly greater than that of controls, as determined by Student's t test (p <
0.01).
We next tested whether 1591-specific Th cells could be restimulated with the
1591-HM variant that had lost all known 1591-specific, CTL-defined antigens.
Since these variant cells no longer have the CTL-defined antigens required for
stimulation of 1591-specific CTL used for readout, we used another IL-2-
dependent CTL line stimulated by an unrelated tumor as indicator. Thus, 2240-
RE tumor-specific CTL and 2240 tumor cells were added to cultures to provide
a readout for 1591-specific Th activity in the experiments of Table 11 . Exp. 1
shows that 1591-specific Th activity was detectable when 1591 antigen was
added, despite relatively high anti-2240 background lytic activity using the 2240
Exp.
Tumor
Sensitization
in vivo
antigen*
Elicitation
in vitro
Blocking mAb
specificity$
Lysis by helper factor-
dependentanti-1591
CTL§
1 - 1591-[A+B-] - 11 ± 3 (control)
2240-REO - 12 ± 4
1130-RE - 15 ± 3
1591-[A+B+] - 37 t6'
1591-[A+B-] - 40 t6'
1591-[A-B*] - 30 ± 5'
2 1591-[A-B`] - - 7 f 2 (control)
1591-[A+B-] - 40 ± 4'
Thy-1.2 37 ± 4'
L3T4 4 ± 1
I-Ak 8 ± 4
Dk 49 ± 4'
3 1591-[A+B+] - - 12 ± 4 (control)
1591-[A+B+] - 62 ± 4'
L3T4 6 ± 1
I-Ak 19 ± 2
Dk 51 ± 5'
4 1591-[A+B+] - - 6 ± 1 (control)
1591-[A+B*] - 59 ± 2'
L3T4 13 ± 3
L3T4 + IL-2 41 ± 3'1558
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TABLE II
Retention ofthe 1591 Lineage-speck Antigen by Highly Malignant 1591
Variant Tumor Cells
* 1591-RE immune spleen cells were cocultured witha 2240-RE-specific IL-2-dependent CTL line (which is usedas a readout for IL-
2 production) . Antigen specificity of the help provided by the 1591-RE spleen cells was measured by the presence or absence of
tumor cellsof the 1591 lineage. 2240-RE cells were alwaysadded to provide antigen forthe antigen-dependentanti-2240 CTL line
used as readout. T cell-depleted filler cells were added toall cultures.
The cloned 2240-specific CTL linewas added at 200 cells per culture. After 7 d of coculture, 16 replicate cultures were tested in a
6-h "Cr-release assay against 2240-RE. The mean percentages oflysis t SEM are reported. Lysis of 2240-RE by 1591 immune cells
or anti-2240.3 CTL cultured alone with appropriate antigen and fillers was 13 and 4%, respectively.
li All responses significantly greater than control cultures (p < 0.0001).
readoutsystem. The relatively high anti-2240background activity wasapparently
due to a primary Th response to 2240, since the 2240 antigen elicited a similar
response from nonsensitized, as well as 1591-sensitized, spleen cells (Exp. 2).
Analysis of different responder/stimulator (R/S) ratios in Exp. 1 indicated that
the maximum specific activity was detected at 2 X 105 responders per culture
(R/S, 100:1), and thus spleen cells at this concentration were cultured with 2240-
RE, anti-2240-RE CTL, and the different 1591 variants as antigen in Exp. 2.
When compared with the parental 1591-RE cells, 1591-HM fully retained the
ability to elicit the increment due to 1591 tumor-specific Th responses (p <
0.0001; Table 11, Exp. 2). Thus, the results of Table 11 are consistent with the
experiments in Fig. 5 and Table 1, which indicated the existence and retention
of a 1591 lineage-specific, Th-recognized antigen expressed independently of
CTL-recognized antigens.
Tumor Variants Lacking CTL-Recognized Antigens Can Induce Tumor Rejec-
tion. We next wished to determine the significance of the response to the
antigen recognized by Th in tumor rejection. Therefore, we determined which
of the antigens recognized by CTL or Th cells was needed to induce protective
1591-specific immunity to challenge in transplantation assay. Tumor-specific
immunity to transplanted UV-induced tumors can be detected after immuniza-
tion with the same tumor and sublethal irradiation, which eliminates detection
of protective immunity generated by primary or crossreactive immune responses
(11). Thus, mice were immunized with variants of the 1591 tumor and control
tumors, and 1 mo later, were challenged with the A-B+ 1591-PRO tumor after
sublethal (600 rad) irradiation . Experiments comparing tumor incidence in
irradiated and unirradiated recipients confirm that radioresistant tumor-specific
immunity can only be induced by preimmunization with tumors of the 1591
lineage (Table 111). The table shows that an A+B- 1591 variant was as effective
as the A+B+ 1591-RE tumor in protecting against a challenge with the A-B+
Tumor antigen*
Lysis by helper
at
factor-dependent
responder/stimulator
anti-2240
ratio of:
CTO
Exp.
Sensitization
in vivo
Elicitation
in vitro
200 100 50 25 12
1 1591-RE 2240-RE 20 ± 3 18 ± 2 20 ± 4 15 ± 2 11 t 2 (control)
1591-RE + 2240-RE 41 ± 21 59 ± 41 34 ± 8 25 ± 4 10 ± 2
2 None 2240-RE - 37 ± 3 - - -
1591-RE 2240-RE - 35 t 3 (control) - - -
1591-RE + 2240-RE - 63 ± 41 - - -
1591-PRO + 2240-RE - 62 ± 51 - - -
1591-HM + 2240-RE - 57 ± 31 - - -TABLE III
1591 Lineage-specific Immune Protection Persists After Irradiation
VAN WAES ET AL.
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* C3H mice received either an intraperitoneal injection of 10' cultured
cells or a subcutaneous implantation of three 1-mm' fragments oftumor
grown in C3H nude or adult-thymectomized, -y-irradiated bone mar-
row-reconstituted C3H mice. 4 wk later, mice received 600 rad or no
irradiation, as indicated, and 24 h later all mice were challenged with
three 1-mm' fragmentsof the 1591-PRO tumor.
$ Number of mice with progressively growing tumors at 6 wk after
challenge per number of mice challenged. The percentage is given in
parentheses. Similar results were obtained in two independent experi-
mentsand, therefore, pooled; each experiment included the four tumors
of the 1591 lineage and twoor threenon-1591 tumors. All animalsthat
had tumors at 6 wk eventually died or were killed when moribund.
Tumors regularly showed an initial period of growth even when later
rejected. Mice that had rejected their tumor by 6 wk remained tumor
free (?3 mo observation period).
4 Notincluded in this tableare mice that were challenged with 1591-PRO
5 mo rather than 1 mo after preimmunization; six mice each were
preimmunized with 2240-RE or 1591-REin thesame experiment. Four
of six of 2240-RE immunized mice developed tumors, while zero of six
1591-RE immunized animals succumbed to progressive tumor growth
when challenged at this later time.
p This 1591-[A-B+] variant is 1591-PRO,derived by selection in vivo (2).
' 1591-[A*B-] is the variant 1591-BS, and 1591-[A-B'] is the variant
1591-AS, both derivedby in vitro selection with 1591-specific CTL (8).
tumor 1591-PRO. This indicated that there was a 1591 lineage-specific antigen
that was independent of the CTL-defined A or B antigens, since transplant
immunity to the A-B' tumor was obtained without prior immunization with the
B antigen. Further experiments showed that the A-B- variant 1591-HM also
induced radioresistant 1591-specific immunity, despite the absence of any de-
tectable CTL-defined antigens on the tumor used for immunization (Fig. 7 b).
While immunization with the A-B- 1591-HM variant provided protection to
1591-PRO tumor challenge (the B+ variant from which 1591-HM had been
derived), none of the tumors of the 1591 lineage could induce protective
immunity against challenge with the rapidly growing 1591-HM tumor itself
(Fig.7a), or to an unrelated progressor tumor, 1316-PRO (Fig. 7c). Thus, these
data indicate the importance of a 1591 lineage-specific antigen that does not
seem to be the target ofprotective immunity, but nevertheless induces immunity
Preimmunization*
Tumor incidence (%)of
1591-PRO[A-B']$
Nonirradiated Irradiated
recipient recipient
2240-RE 1/7 (14)4 7/7(100)
1316-RE 4/11 (36) 8/8(100)
1130-RE 12/18(67) 5/5(100)
1591-[A*B*] 1/33 (3)4 1/8(13)
1591-[A+B-]' 1/8 (13) 1/7(14)
1591-[A-B+]' 0/8 (0) 1/8(13)
1591-[A-B+]1 0/58(0) 0/5(0)
Normal fibroblasts 5/5 (100) ND
None 50/59(85) 6/8(75)1560
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FIGURE 7.
￿
1591 tumor lineage-specific protection conferred by immunization with variants
not sharing 1591-specific, CTL-recognized antigens . Mice were immunized subcutaneously
with three 1-mm' 7-irradiated (10,000R) tumor fragments of 1591-BS, 1591-HM or 1591-
PRO variants, or the unrelated UV-induced 1316-RE tumor. One mo later, mice were
sublethally irradiated (600R), and after 24 h groups of 5 mice were challenged with two 1-
mm" fragments of 1591-HM (a), 1591-PRO (b) or 1316-PRO (c) . Tumor volumes were
calculated from caliper measurements in three dimensions. Death of 1591-HM-challenged
mice for all immunized groups is indicated by crosses .
to challenge with a tumor of the same lineage that retains a CTL-defined target
structure .
Discussion
This study shows that tumor-specific antigens can be retained by cancer cells
isolated during progression from a rather "benign" RE tumor to an HM cancer .
We dissected the components ofT cell-mediated immunity to a tumor-specific
antigen, and found that the antigens recognized byCTL were lost (Fig . 3), while
those recognized by Th cells were retained (Fig . 5, Table II) . Such Th cell-
recognized antigens were even retained by cancer cells isolated from a distant
metastasis (Fig . 5) . It seems unlikely for several reasons that the Th-recognized
antigens merely represent retained or quantitatively reduced levels of CTL-
recognized antigens . First, we excluded the possibility that the variants had
retained the CTL-defined antigens by becoming resistant to lysis (Fig . 3), or
through loss ofMHC class I antigens that restrict Lyt-2+CTL responses (Fig. 4) .
Second, the antigenic differences among different 1591 tumor variants were not
due to differences in quantitative levels of a single antigen, since we have shown
that the CTL-defined antigens A and B can be lost independently in any
combination as well as altogether by selection with A andB antigen-specific CTL
in vitro (12) ; further, we now know that loss of the A antigen results from
complete loss of the gene encoding this antigen (28) . Third, it is likely that the
Th antigen is completely independent of the A and B antigens since we have
shown that Th responses and tumor rejection do not require sharing or the
presence ofA and B antigens during sensitization and elicitation (Tables I-III ;
Figs . 5 and 7) . Thus, it appears that the Th cell-recognized antigens represent
an independently expressed tumor-specific antigen or complex ofantigens . TheseVAN WAES ET AL.
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Th cell-recognized antigensare retained during tumor selection and are specific
for all tumor variants derived from the same original tumor, i. e., these antigens
are "lineage-specific."
The demonstrated persistence of certain tumor-specific antigens and the loss
of others as a result of host-selective pressures may provide important clues
regarding the mechanisms of tumor recognition and destruction in vivo. The
results suggest that tumor-specific CTL directly recognize and destroy tumor
cells expressing the appropriate target structures in vivo, and hence, exert direct
selective pressure upon the tumor for the generation ofantigen-loss variants. In
contrast, the lineage-specific antigens recognized by Th cells are not a direct
target ofimmune destruction in vivosince theypersistduring tumor progression,
and since such antigens provide no protection to 1591-HM in 1591-immune
mice (Fig. 7). However, we found that the antigens retained by 1591-HM play a
significant rolein tumorrejection, since immunization with 1591-HM mayinduce
protective immunity to parental RE or variant PRO cells that retain target
antigens recognized by CTL (Fig. 7). Thus, the Th-recognized antigens may also
be distinguished by an ability to induce, but not serve as the target of tumor
rejection. The presence of these antigens would therefore have been missed by
classical tumor transplantation assays in which the same HM tumor was used for
immunization and challenge. Thus, similar Th-defined, unique tumor-specific
antigens may not have been detected on other HM tumors that have previously
been considered to be nonantigenic.
To account for the retention ofTh-recognized antigens, it may be important
that, unlike the CTL-recognized antigens, the Th cell-recognized antigen(s) are
not recognized directly on the tumor cell surface. The observed blocking of the
tumor-specific Th responses by anti-la antibody suggests that Th cells recognize
this antigen in the context of I-A class II MHC determinants, and indeed both
the cells required for the DTH and Th responses were found to belong to the
L3T4+ subset; i.e., cells that recognize antigen in the context of MHC class 11
molecules (29). Since the 1591 tumor is itself la- (Fig. 4), it is likely that the Th-
recognized antigens are only recognized on la' APCs and not directly on tumor
cells.
Possibly the PRO and HM tumors have retained Th cell-recognized antigens
by selectively losing susceptibility to lymphotoxin, a factor that mediates killing
by Th cells (30-32).At present, we know that these tumors are resistant to
macrophage tumor necrosis factor and to B cell lymphotoxin (33). B cell lym-
photoxin seems to use a similar effector pathway as tumor necrosis factor (33),
and it appears to be closely related to T cell lymphotoxin, as shown by DNA
sequence homology (N. Ruddle, personal communication) . This question may
be critically addressed when purified recombinant murine lymphotoxin of the
type produced by Th cells becomes available.
Tumor-specific Th cells, though not directly tumoricidal, may play an impor-
tant role in tumor rejection through the release of lymphokines that activate
other effector cells (9, 34), and we have shown such cooperation between Th
cells and CTL (Fig.6). Lake and Mitchison (35) predicted some time ago that Th
cells and CTL could cooperate by "associative recognition" ofantigens expressed
independently, and our findings are consistent with this hypothesis.1562
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In agreement with others (36), we found that unrelated UV-induced fibrosar-
comas provided varying levels of crossprotective immunity against a PRO tumor
in unirradiated mice. However, the mechanism and importance of crossprotec-
tion is unclear. As noted by Brent and Medawar (37), immune responses acquire
radioresistance once lymphocytes are exposed to antigen. Unlike immunity that
is specific for individual tumors, crossprotection is sensitive to low doses of
ionizing radiation (Table III) and fades with time (see footnote of Table III).
Thus at present, there is no evidence for an antigen-specific response to a
crossprotective antigen that would be commonly expressed by independently
induced tumors, since radioresistant immunity (11, this study), CTL (2, 12, 38),
and Th cell responses (this study) show specificity for antigens that are individ-
ually specific for each independently induced tumor (see reference 1 for review).
Therefore, we have concentrated in the present study on developing an under-
standing of the tumor-specific protection that is radioresistant, long-lived, and
antigen specific.
Th cell-recognized antigens could represent target structures for immuno-
therapy, but at present, we do not know if tumoricidal effector cells could be
induced to such antigens. Tumor lineage-specific Th cell-recognized-antigens
mighthave a distinct advantageover artifically introduced helper cell-recognized
antigens, such as those provided by direct injection of TNP (39) or adjuvants
into a tumor mass. Only the lineage-specific antigens would be present on MET
or deeply invasive tumor cells. If specific antibodies could be generated, such
lineage-specific antigens might also be useful as diagnostic markers to identify
cancer cells wherever they may spread during the course of disease, and to
distinguish them from a second primary malignancy. Since these Th-recognized
antigens appear to be individually specific for each independentlyderived tumor,
it would be interesting to determine if different Th-recognized antigens belong
to a family of related molecules. We do not know if the differences in recognition
of Th cell and CTL-recognized antigens are due to distinct molecular properties
that determine their association with different MHC antigens or T cell receptors.
As an alternative hypothesis, we propose that Th cell-recognized antigens may
represent intracellular determinants, which can be recognized only after antigen
presentation. Presumably, mutations resulting in changes in intracellular mole-
cules are as likely as those affecting cell surface determinants . This hypothesis
can be tested, since methods are available for screening mAbs to intracellular as
well as cell surface antigens. Since Th-recognized antigens are retained during
tumor progression they might well reflect an alteration essential to the expression
of the malignant phenotype.
Summary
We have studied the components of a complex of tumor-specific antigens to
determine if all of the components of the complex were lost during progression
from a rather benign regressor tumor to a highly malignant (HM) cancer. We
find that the HM tumor cells have lost antigens recognized by CTL but retained
antigens recognized by Th cells. Immunization with variants expressing Th-
defined antigens induced tumor-specific immunity to challenge with a parental
variant that expressed a CTL-recognized target antigen, but did not induceimmunity to challenge with the variant that expressed the Th-defined antigen
alone. Together, these findings suggested that Th cells fail to exert direct
selective pressure upon the tumor, resulting in retention of "lineage-specific,"
Th-recognized antigens by highly immunoselected variants. Possible advantage
could be taken of this fact for the development of specific immunotherapy.
We thank Dr. Donald Rowley for his encouragement and stimulating discussion, and Drs.
Donald Rowley and Jose Quintans for review of the manuscript, Dr. Stephen Miller for
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